Biocept announces laboratory testing collaboration with Quest Diagnostics » 08:2006/2206/22/21
Biocept (BIOC) announced…
Biocept (BIOC) announced a collaboration with Quest Diagnostics (DGX) to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel. The Biocept Target Selector NGS-based liquid biopsy assay is a less invasive, lab developed test that can be used for genomic profiling in patients with advanced non-small cell lung cancer, or NSCLC, to help qualify them for advanced targeted therapies and monitor the effectiveness of treatment. With a physician order, patients will be able to provide a blood specimen for testing at one of Quest's 2,200 located patient service centers across the United States. The two parties expect the service to be available to Quest Diagnostics' providers and patients in Q4.
|Over a week ago|
Biocept received over 420,000 samples for SARS-CoV-2 testing since June 2020 » 08:2006/1506/15/21
Biocept announced that it…
Biocept announced that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020. The samples are processed using Biocept's RT-PCR-based technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory in San Diego.
Biocept, and CLEARED4 team to manage testing reporting for Biocept customers » 08:4906/0906/09/21
Biocept and CLEARED4 have…
Biocept and CLEARED4 have partnered to develop a system for tracking and managing COVID-19 testing requirements and test results for Biocept customers. The new service will leverage CLEARED4's comprehensive health platform, allowing organizations to incorporate customized protocols and requirements for testing students, employees and others. The platform will integrate results from Biocept's RT-PCR-based COVID-19 testing in real-time, and administrators will be able to monitor the program and results for their organizations via a secure dashboard.
|Over a month ago|
Biocept reports Q1 EPS 19c vs. ($1.06) a year ago. » 16:0805/1205/12/21
Reports Q1 revenue…
Reports Q1 revenue $17.8M, one estimate $13.67M. Biocept reported cash and cash equivalents as of March 31, 2021 of $14.2 million, compared with $14.4M as of December 31, 2020.
Biocept to provide COVID-19 testing to 116 California community colleges » 08:2904/2804/28/21
Biocept has partnered…
Biocept has partnered with the Foundation for California Community Colleges to make COVID-19 testing available to the 116 California community colleges and their more than 2.1M students. Through the Foundation's CollegeBuys program, Biocept's PCR-based COVID-19 test is now available for community colleges to purchase for students, faculty and staff. Access to and availability of testing will provide information needed to help protect the safety of campus populations and reduce the spread of the virus on campuses and in surrounding communities if/when colleges return from the current remote learning environment as a result of the COVID-19 pandemic.
Biocept announces full commercial launch of CNSide » 08:1904/2104/21/21
Biocept announced the…
Biocept announced the full commercial launch of CNSide, its cerebrospinal fluid, or CSF, assay designed to better detect and manage treatment of metastatic cancers involving the central nervous system, or CNS. The assay, initially introduced in January 2020, has the ability to offer a timely and accurate method to diagnose disease, identify actionable biomarkers, and assess response to therapy, potentially impacting life expectancy and quality of life.
Biocept has received over 350,000 samples for SARS-CoV-2 testing services » 08:0904/1404/14/21
Biocept announced that…
Biocept announced that since the company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing. These samples are processed using Biocept's RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego. "We are exceptionally proud to continue supporting our community with SARS-CoV-2 testing and providing healthcare providers with rapid turnaround of valuable information to help contain viral spread," said Michael Nall, President and CEO of Biocept. "RT-PCR testing for COVID-19 currently remains an important component of our business while we focus on our core business, including the opportunity to serve patients diagnosed with advanced cancer through commercializing our differentiated CNSide(TM) neuro-oncology offerings."
Biocept to hold a conference call » 11:5504/0804/08/21
Management holds a KOL…
Biocept to hold a conference call » 04:5504/0804/08/21
Management holds a KOL…
Biocept to hold a conference call » 15:1604/0504/05/21
Management holds a KOL…